Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 7, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Stephen Willey Upgraded (ALNY) to Strong Buy and Increased Target to $125 on, Aug 7th, 2018
Stephen Willey of Stifel, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Strong Buy and Increased Target from $95 to $125 on, Aug 7th, 2018.
Stephen has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 1 agrees with Stephen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $99 on, Friday, August 3rd, 2018
This is the rating of the analyst that currently disagrees with Stephen
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $134 on, Friday, May 4th, 2018
